Hanhart J, et al. - Researchers evaluated the mortality related to the intravitreal injections of bevacizumab for age-related macular degeneration (AMD) in cases previously diagnosed with acute myocardial infarct (MI). Findings demonstrated an association of increased mortality with the use of intravitreal bevacizumab in AMD patients after MI, compared to age- and gender-matched post-MI patients with no exposure to any anti-VEGF agent. While offering bevacizumab to AMD patients following MI, caution was recommended.